Table 4. Characteristics of the BMT procedure and its related complications.

Patient	Donor	Year of BMT	Age at BMT (month)	Follow-up (months)	Conditioning	Graft	Prophylaxis	Neutrophils (days)	Acute GVHD	Febrile episodes
P1	MMRD	2005	4	36	No	PBSC/CD34	No	25	grade IV	2
P2	MMRD	20052006	47	22	No	PBSC/CD34	No	28	grade IV	2
P3	MRD	1998	7.5	146	No	BM	No	13	No	1
P4	MMRD	2002	4	92	No	PBSC/CD34	No	10	No	0
P5	MMRD	2000	1.5	132	No	PBSC/CD34	No	10	grade III	2
P6	MRD	2000	1	119	No	BM	No	11	No	1
P7	MMRD	1997	5	150	Bu Cy ATG	PBSC/CD34	CSA	8	grade III	2
P8	MRD	2008	7.5	25	Tre Flu Thi	BM	CSA+MTX	15	grade II	1
P9	MUD	2010	5	4	Bu Cy ATG	UCB	CSA	13	grade I	1
P10	MMRD	2009	5	9	Flu, Mel, Thi OKT3	PBSC/CD34	MMF	9	No	2

MRD - match related donors, MUD - match unrelated donor, MMRD - mismatch related donor, Bu – Busulfan, Cy – cyclophosphamide, ATG – anti thymocytes globulin, Tre – Treosulfan, Flu – Fludarabine, Thi – Thiotepa, Mel – melphalan, PBSC –peripheral blood stem cells, BM – Bone marrow, UCB – Umbilical cord blood, CSA – Cyclosporin, MTX – methotrexate, MMF – mycophenolate mofetil.